Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeXun Biosciences CoROCO:6986 +0.72%42 EV-to-EBITDA is 8.01 as of Sep. 05, 2026, which is 47% below its 10-year median of 15.09. GuruFocus rates ROCO:6986 with a GF Score™ of 42/100 and a GF Value™ of NT$109.72 (Significantly Undervalued). Among 403 Biotechnology companies, HeXun Biosciences Co ranks better than 61.54% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HeXun Biosciences Co's enterprise value is NT$1,384.9 Mil.
HeXun Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$172.9 Mil. Therefore, HeXun Biosciences Co's EV-to-EBITDA for today is 8.01.
The historical rank and industry rank for HeXun Biosciences Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6986'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.66 Med: 15.09 Max: 79.54
Current: 8.01
During the past 6 years, the highest EV-to-EBITDA of HeXun Biosciences Co was 79.54. The lowest was 6.66. And the median was 15.09.
ROCO:6986's EV-to-EBITDA is ranked better than 61.54% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:6986: 8.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HeXun Biosciences Co (ROCO:6986) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HeXun Biosciences Co's PE Ratio (TTM) for today is calculated as:
HeXun Biosciences Co's share price for today is NT$41.80.
HeXun Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for HeXun Biosciences Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's EV-to-EBITDA falls into.
HeXun Biosciences Co's current Enterprise Value is NT$1,384.9 Mil.
HeXun Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$172.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) has a EV-to-EBITDA of 8.01 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HeXun Biosciences Co. This is 47% below median its historical median of 15.09. Over the past decade, HeXun Biosciences Co's EV-to-EBITDA has ranged from 6.66 to 79.54. According to the industry distribution chart, HeXun Biosciences Co ranks #155 out of 403 companies in the Biotechnology industry, placing it in the top 38.5%.
Is HeXun Biosciences Co's EV-to-EBITDA too high?
HeXun Biosciences Co's current EV-to-EBITDA of 8.01 is 47% below median its 10-year median of 15.09. Over the past 10 years, this metric has ranged from a low of 6.66 to a high of 79.54. The Biotechnology industry median EV-to-EBITDA is 13.70. HeXun Biosciences Co's value of 8.01 is 41.5% below this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #155 out of 403 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HeXun Biosciences Co has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #155 out of 403 companies for EV-to-EBITDA. This puts HeXun Biosciences Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. HeXun Biosciences Co's value of 8.01 is 41.5% below this benchmark. Historically, HeXun Biosciences Co's own EV-to-EBITDA has ranged from 6.66 to 79.54 over the past decade. While the company's 10-year median is 15.09 vs. the industry median of 13.70, HeXun Biosciences Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current EV-to-EBITDA of 8.01 is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HeXun Biosciences Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current EV-to-EBITDA is 8.01, which is 47% below median its own 10-year median of 15.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, HeXun Biosciences Co (ROCO:6986) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$109.72, compared to a current price of NT$41.80 — trading 61.9% below its estimated fair value. The current EV-to-EBITDA is 8.01, which is 47% below median its 10-year median of 15.09 and 41.5% below the Biotechnology industry median of 13.70. HeXun Biosciences Co's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current EV-to-EBITDA is 8.01 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?
Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued.
The current stock price of NT$41.80 is trading 61.9% below its estimated GF Value™ of NT$109.72.
GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.
Key valuation signals for ROCO:6986:
EV-to-EBITDA: 8.01 (47% below median its 10-year median of 15.09)
GF Value™: NT$109.72 vs. price of NT$41.80 (61.9% below fair value)
Industry Position: 41.5% below the Biotechnology median (#155 of 403)
No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
42GF Score
Get the complete analysis for ROCO:6986
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
